The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Engineering Natural Killer Cells for Cancer Immunotherapy
Open accessAbstract
The past several years have seen tremendous advances in the engineering of immune effector cells as therapy for cancer. While chimeric antigen receptors (CARs) have been used extensively to redirect the specificity of autologous T cells against hematological malignancies with striking clinical results, studies of CAR-modified natural killer (NK) cells have been largely preclinical. In this review, we focus on recent advances in NK cell engineering, particularly on preclinical evidence suggesting that NK cells may be as effective as T cells in recognizing and killing targets after genetic modification. We will discuss strategies to introduce CARs into both primary NK cells and NK cell lines in an effort to provide antigen specificity, the challenges of manufacturing engineered NK cells, and evidence supporting the effectiveness of this approach from preclinical and early-phase clinical studies using CAR-engineered NK cells. CAR-NK cells hold great promise as a novel cellular immunotherapy against refractory malignancies. Notably, NK cells can provide an "off-the-shelf" product, eliminating the need for a personalized and patient-specific product that plagues current CAR-T cell therapies. The ability to more potently direct NK cell-mediated cytotoxicity against refractory tumors through the expression of CAR is likely to contribute to the recent paradigm shift in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · cited 2×
“19/IL15)(82) that (1) incorporates the gene for CAR CD19 to redirect specificity to CD19; (2) ectopically produces IL-15, a cytokine crucial for NK cell survival and proliferation(103); and (3) expresses a suicide gene, inducible caspase-9 (iC9), that can be pharmacologically activated to eliminate transduced cells as…”
Self-citationHuman natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
Licensing of natural killer cells by host major histocompatibility complex class I molecules
Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y.-J., Yang, L., French, A. R., Sunwoo, J. B., Lemieux, S., Hansen, T. H., et al. (2005) · Nature · doi:10.1038/nature03847 · Cited by 1,340
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
An Activating Immunoreceptor Complex Formed by NKG2D and DAP10
Wu, J., Song, Y., Bakker, A. B. H., Bauer, S., Spies, T., Lanier, L. L., & Phillips, J. H. (1999) · Science · doi:10.1126/science.285.5428.730 · Cited by 1,039
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013) · Immunology · doi:10.1111/imm.12036 · Cited by 815
Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Mamessier, E., Sylvain, A., Thibult, M.-L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Gonçalves, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 681
Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605
Brudno, J. N., Somerville, R. P. T., Shi, V., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea-Banacloche, J. C., Pavletic, S. Z., Hickstein, D. D., Lu, T. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5929 · Cited by 605
Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity
Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., Modlich, U., Beier, R., Göhring, G., Steinemann, D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007280 · Cited by 562
Campbell, J. J., Qin, S., Unutmaz, D., Soler, D., Murphy, K. E., Hodge, M. R., Wu, L., & Butcher, E. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6477 · Cited by 517
Cruz, C. R. Y., Micklethwaite, K. P., Savoldo, B., Ramos, C. A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A. J., Ito, S., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506741 · Cited by 508
Self-citationHuman natural killer cell development and biology
Farag, S. S., & Caligiuri, M. A. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.10.001 · Cited by 506
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86721 · Cited by 500
Self-citationTreatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Zhao, Y., Moon, E., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 450
Tagaya, Y., Bamford, R. N., DeFilippis, A. P., & Waldmann, T. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80246-0 · Cited by 440
Chu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., Le, C. T., Marsh, S. G. E., Guethlein, L. A., Parham, P., Miller, J. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-171926 · Cited by 434
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008) · Cytotherapy · doi:10.1080/14653240802301872 · Cited by 434
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
Natural killer cell biology: An update and future directions
Campbell, K. S., & Hasegawa, J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.006 · Cited by 416
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
Adoptive cellular therapy: A race to the finish line
June, C. H., Riddell, S. R., & Schumacher, T. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3643 · Cited by 403
Olson, J. A., Leveson-Gower, D. B., Gill, S., Baker, J., Beilhack, A., & Negrin, R. S. (2010) · Blood · doi:10.1182/blood-2009-05-222190 · Cited by 384
Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., & Costello, R. T. (2007) · Blood · doi:10.1182/blood-2005-08-027979 · Cited by 380
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
De Maria, A., Bozzano, F., Cantoni, C., & Moretta, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012356108 · Cited by 344
Expression and Function of TNF-Related Apoptosis-Inducing Ligand on Murine Activated NK Cells
Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., & Yagita, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1906 · Cited by 340
Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
Chang, Y.-H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Suck, G., Odendahl, M., Nowakowska, P., Seidl, C., Wels, W. S., Klingemann, H. G., & Tonn, T. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1761-x · Cited by 328
El-Sherbiny, Y. M., Meade, J. L., Holmes, T. D., McGonagle, D., Mackie, S. L., Morgan, A. W., Cook, G., Feyler, S., Richards, S. J., Davies, F. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4230 · Cited by 321
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, A., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 305
Berg, M., Lundqvist, A., McCoy, P., Samsel, L., Fan, Y., Tawab, A., & Childs, R. (2009) · Cytotherapy · doi:10.1080/14653240902807034 · Cited by 304
Upshaw, J. L., Arneson, L. N., Schoon, R. A., Dick, C. J., Billadeau, D. D., & Leibson, P. J. (2006) · Nature Immunology · doi:10.1038/ni1325 · Cited by 300
Leong, J. W., Chase, J. M., Romee, R., Schneider, S. E., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.01.006 · Cited by 285
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Rezvani, K., & Rouce, R. H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00578 · Cited by 272
Self-citationPassweg, J. R., Tichelli, A., Meyer-Monard, S., Heim, D., Stern, M., Kühne, T., Favre, G., & Gratwohl, A. (2004) · Leukemia · doi:10.1038/sj.leu.2403524 · Cited by 270
Are natural killer cells superior CAR drivers?
Klingemann, H. (2014) · OncoImmunology · doi:10.4161/onci.28147 · Cited by 270
Woll, P. S., Grzywacz, B., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R., & Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2008-06-165225 · Cited by 268
Jiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F., Zeng, T., Huang, H., Zhang, X., Sun, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.001 · Cited by 267
Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma
Raffaghello, L., Prigione, I., Airoldi, I., Camoriano, M., Levreri, I., Gambini, C., Pende, D., Steinle, A., Ferrone, S., & Pistoia, V. (2004) · Neoplasia · doi:10.1593/neo.04316 · Cited by 264
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92
Maki, G., Klingemann, H.-G., Martinson, J. A., & Tam, Y. K. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/152581601750288975 · Cited by 262
Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment
Joncker, N. T., Shifrin, N., Delebecque, F., & Raulet, D. H. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100570 · Cited by 259
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Töpfer, K., Cartellieri, M., Michen, S., Wiedemuth, R., Müller, N., Lindemann, D., Bachmann, M., Füssel, M., Schackert, G., & Temme, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400330 · Cited by 249
Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
Carlsten, M., & Childs, R. W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00266 · Cited by 243
Advantages and applications of CAR-expressing natural killer cells
Glienke, W., Esser, R., Priesner, C., Suerth, J. D., Schambach, A., Wels, W. S., Grez, M., Kloess, S., Arseniev, L., & Koehl, U. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00021 · Cited by 243
Chen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., Chen, L., Wang, Y., Wang, H., Yi, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8526 · Cited by 242
Stringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087536 · Cited by 231
Self-citationMoretta, L., Locatelli, F., Pende, D., Marcenaro, E., Mingari, M. C., & Moretta, A. (2011) · Blood · doi:10.1182/blood-2010-08-264085 · Cited by 229
CAR therapy: the CD19 paradigm
Sadelain, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80010 · Cited by 227
Romanski, A., Uherek, C., Bug, G., Seifried, E., Klingemann, H., Wels, W. S., Ottmann, O. G., & Tonn, T. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12810 · Cited by 220
Ghosh, A., Smith, M., James, S. E., Davila, M. L., Velardi, E., Argyropoulos, K. V., Gunset, G., Perna, F., Kreines, F. M., Levy, E. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4258 · Cited by 219
Zhou, X., Dotti, G., Krance, R. A., Martinez, C. A., Naik, S., Kamble, R. T., Durett, A. G., Dakhova, O., Savoldo, B., Di Stasi, A., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628354 · Cited by 216
Müller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H.-G., Tonn, T., & Wels, W. S. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0383-3 · Cited by 212
Tettamanti, S., Marin, V., Pizzitola, I., Magnani, C. F., Giordano Attianese, G. M. P., Cribioli, E., Maltese, F., Galimberti, S., Lopez, A. F., Biondi, A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12282 · Cited by 211
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., et al. (2011) · Blood · doi:10.1182/blood-2011-06-360255 · Cited by 208
Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M., & Rossig, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2810 · Cited by 206
A Central Role for Death Receptor-Mediated Apoptosis in the Rejection of Tumors by NK Cells
Screpanti, V., Wallin, R. P. A., Ljunggren, H.-G., & Grandien, A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.4.2068 · Cited by 201
Shah, N., Martin-Antonio, B., Yang, H., Ku, S., Lee, D. A., Cooper, L. J. N., Decker, W. K., Li, S., Robinson, S. N., Sekine, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076781 · Cited by 199
Self-citationEngineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R., Blankenstein, T., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 197
Boissel, L., Betancur, M., Lu, W., Krause, D., Van Etten, R., Wels, W., & Klingemann, H. (2013) · OncoImmunology · doi:10.4161/onci.26527 · Cited by 194
Esser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
Oelsner, S., Friede, M. E., Zhang, C., Wagner, J., Badura, S., Bader, P., Ullrich, E., Ottmann, O. G., Klingemann, H., Tonn, T., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2016.10.009 · Cited by 188
Genßler, S., Burger, M. C., Zhang, C., Oelsner, S., Mildenberger, I., Wagner, M., Steinbach, J. P., & Wels, W. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1119354 · Cited by 187
Yagita, M., Huang, C., Umehara, H., Matsuo, Y., Tabata, R., Miyake, M., Konaka, Y., & Takatsuki, K. (2000) · Leukemia · doi:10.1038/sj.leu.2401769 · Cited by 186
Sahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Lin, K.-W., Jares, A., Firor, A. E., Shuai, X., Salman, H., Golightly, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.8 · Cited by 184
Jochems, C., Hodge, J. W., Fantini, M., Fujii, R., Morillon, Y. M., Greiner, J. W., Padget, M. R., Tritsch, S. R., Yok Tsang, K., Campbell, K. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13411 · Cited by 182
Shimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T., Eldridge, P., Leung, W., & Campana, D. (2012) · Cytotherapy · doi:10.3109/14653249.2012.671519 · Cited by 177
Chu, Y., Hochberg, J., Yahr, A., Ayello, J., van de Ven, C., Barth, M., Czuczman, M., & Cairo, M. S. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0114 · Cited by 174
Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
Hermanson, D. L., & Kaufman, D. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00195 · Cited by 172
Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
Gras Navarro, A., Björklund, A. T., & Chekenya, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00202 · Cited by 167
Boissel, L., Betancur, M., Wels, W. S., Tuncer, H., & Klingemann, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.024 · Cited by 166
Use of Allogeneic NK Cells for Cancer Immunotherapy
Geller, M. A., & Miller, J. S. (2011) · Immunotherapy · doi:10.2217/imt.11.131 · Cited by 162
Rouce, R. H., Shaim, H., Sekine, T., Weber, G., Ballard, B., Ku, S., Barese, C., Murali, V, Wu, M.-F., Liu, H., et al. (2016) · Leukemia · doi:10.1038/leu.2015.327 · Cited by 161
Self-citationOevermann, L., Michaelis, S. U., Mezger, M., Lang, P., Toporski, J., Bertaina, A., Zecca, M., Moretta, L., Locatelli, F., & Handgretinger, R. (2014) · Blood · doi:10.1182/blood-2014-03-565069 · Cited by 146
Li, L., Liu, L. N., Feller, S., Allen, C., Shivakumar, R., Fratantoni, J. C., Wolfraim, L. A., Fujisaki, H., Campana, D., Chopas, N., et al. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.61 · Cited by 144
Yoon, S. R., Lee, Y. S., Yang, S., Ahn, K. H., Lee, J.-H., Lee, J.-H., Kim, D. Y., Kang, Y., Jeon, M., Seol, M., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.304 · Cited by 129
Lin, W., Voskens, C., Zhang, X., Schindler, D. G., Wood, A., Burch, E. E., Wei, Y., Chen, L., Tian, G., Tamada, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122465 · Cited by 124
Bachanová, V., & Miller, J. S. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014011091 · Cited by 117
Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Wu, C., & Dunbar, C. E. (2011) · Frontiers of Medicine · doi:10.1007/s11684-011-0159-1 · Cited by 114
Liu, Y., Wu, H.-W., Sheard, M. A., Sposto, R., Somanchi, S. S., Cooper, L. J. N., Lee, D. A., & Seeger, R. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1243 · Cited by 110
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
Koehl, U., Kalberer, C. P., Spanholtz, J., Lee, D. A., Miller, J. S., Cooley, S., Lowdell, M. W., Uharek, L., Klingemann, H., Curti, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115178 · Cited by 110
Kärre, K. (2002) · Science · doi:10.1126/science.1070538 · Cited by 109
Kailayangiri, S., Altvater, B., Spurny, C., Jamitzky, S., Schelhaas, S., Jacobs, A. H., Wiek, C., Roellecke, K., Hanenberg, H., Hartmann, W., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1250050 · Cited by 104
Huenecke, S., Zimmermann, S. Y., Kloeß, S., Esser, R., Brinkmann, A., Tramsen, L., Koenig, M., Erben, S., Seidl, C., Tonn, T., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181bb46f7 · Cited by 104
First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL
Qasim, W., Amrolia, P. J., Samarasinghe, S., Ghorashian, S., Zhan, H., Stafford, S., Butler, K., Ahsan, G., Gilmour, K. C., Adams, S. P., et al. (2015) · Blood · doi:10.1182/blood.v126.23.2046.2046 · Cited by 101
Bradley, M., Zeytun, A., Rafi-Janajreh, A., Nagarkatti, P. S., & Nagarkatti, M. (1998) · Blood · doi:10.1182/blood.v92.11.4248 · Cited by 99
Romain, G., Senyukov, V., Rey-Villamizar, N., Merouane, A., Kelton, W., Liadi, I., Mahendra, A., Charab, W., Georgiou, G., Roysam, B., et al. (2014) · Blood · doi:10.1182/blood-2014-04-569061 · Cited by 98
Natural killer cells in the treatment of high-risk acute leukaemia
Locatelli, F., Moretta, F., Brescia, L. P., & Merli, P. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.004 · Cited by 94
Miller, J. S., Rooney, C. M., Curtsinger, J., McElmurry, R. T., McCullar, V., Verneris, M. R., Lapteva, N., McKenna, D. H., Wagner, J. E., Blazar, B. R., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.05.004 · Cited by 88
Natural killer cells: a review of manufacturing and clinical utility
Koepsell, S. A., Miller, J. S., & McKenna, D. H. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03724.x · Cited by 88
Chimeric antigen receptors: driving immunology towards synthetic biology
Sadelain, M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.06.004 · Cited by 85
Kloeß, S., Huenecke, S., Piechulek, D., Esser, R., Koch, J., Brehm, C., Soerensen, J., Gardlowski, T., Brinkmann, A., Bader, P., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.201040568 · Cited by 83
Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors
Suerth, J. D., Morgan, M. A., Kloeß, S., Heckl, D., Neudörfl, C., Falk, C. S., Koehl, U., & Schambach, A. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1327-6 · Cited by 82
Swift, B. E., Williams, B. A., Kosaka, Y., Wang, X.-H., Medin, J. A., Viswanathan, S., Martínez‐López, J., & Keating, A. (2012) · Haematologica · doi:10.3324/haematol.2011.054254 · Cited by 74
Terszowski, G., Klein, C., & Stern, M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400288 · Cited by 73
Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
Tassev, D. V., Cheng, M., & Cheung, N. K. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.66 · Cited by 72
Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody
Zhang, G., Liu, R., Zhu, X., Wang, L., Ma, J., Han, H., Wang, X., Zhang, G., He, W. Z., Wang, W., et al. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.45 · Cited by 70
Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
Davies, J. O. J., Stringaris, K., Barrett, A. J., & Rezvani, K. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.009 · Cited by 65
Self-citationWagner, J. A., Berrien-Elliott, M. M., Rosario, M., Leong, J. W., Jewell, B. A., Schappe, T., Abdel-Latif, S., & Fehniger, T. A. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.11.018 · Cited by 62
Sekine, T., Marin, D., Cao, K., Li, L., Mehta, P., Shaim, H., Sobieski, C. E., Jones, R. B., Oran, B., Hosing, C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-706317 · Cited by 61
Self-citationKwon, H.-J., Kim, N., & Kim, H. S. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.42 · Cited by 53
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in Human and Other Primate Cell Lines
Uphoff, C. C., Denkmann, S. A., Steube, K. G., & Drexler, H. G. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/904767 · Cited by 51
Natural killer cell therapy in children with relapsed leukemia
Rubnitz, J. E., Inaba, H., Kang, G., Gan, K., Hartford, C. M., Triplett, B. M., Dallas, M. H., Shook, D. R., Gruber, T. A., Pui, C., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25555 · Cited by 47
Cellular therapy of cancer with natural killer cells—where do we stand?
Klingemann, H. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.03.011 · Cited by 37
Lowe, E. L., Truscott, L. C., & Oliveira, S. N. D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3684-7_20 · Cited by 37
Satwani, P., Bavishi, S., Saha, A., Zhao, F., Ayello, J. S., van de Ven, C., Chu, Y., & Cairo, M. S. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.008 · Cited by 29
Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives.
Baum, C., & Fehse, B. (2003) · PubMed · Cited by 29
Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia
Weitzman, J. I., Betancur, M., Boissel, L., Rabinowitz, A. P., Klein, A. K., & Klingemann, H. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903026500 · Cited by 25
Recent advances in T‐cell immunotherapy for haematological malignancies
Rouce, R. H., Sharma, S., Huynh, M., & Heslop, H. E. (2016) · British Journal of Haematology · doi:10.1111/bjh.14470 · Cited by 25
Self-citationJin, F., Lin, H. P., Gao, S., Hu, Z., Zuo, S., Liguang, S., Jin, C., Li, W., & Yang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.13007 · Cited by 24
Hassuneh, M. R., Nagarkatti, P., & Nagarkatti, M. (1997) · Blood · doi:10.1182/blood.v89.2.610 · Cited by 20
Cited by
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Self-citationTumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
NK cell-based cancer immunotherapy: from basic biology to clinical development
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01014-w · Cited by 689
Metadata
- Authors
- Rezvani, K., Rouce, R., Liu, E., & Shpall, E.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 25
- Issue
- 8
- Pages
- 1769-1781
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2626153771
- Cited by
- 453
- References
- 133
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.